spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:   RT Technology 

 HSMN NewsFeed - 10 Aug 2018
Nuvo Pharmaceuticals(TM) Announces Letter of Intent to Acquire Commercial Products and Infrastructure from Aralez Pharmaceuticals
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 1 Jun 2015
POZEN Announces Retirement of Founder, Chairman and CEO Dr. John R. Plachetka; Adrian Adams Named as CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 May 2014
POZEN Announces U.S. Rights for Treximet(R) to Be Acquired by Pernix Therapeutics
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 15 Apr 2011
Preliminary Injunction Ordered in POZEN Treximet Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 15 Apr 2008
Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Jan 2008
POZEN Submits Human Lymphocyte Study for Treximet(TM) (Formerly Known as Trexima(TM))
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Nov 2007
Pozen Announces Trexima(TM) (Sumatriptan Succinate and Naproxen Sodium) Amended Response Accepted for Review by FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Oct 2007
POZEN Submits Response to Approvable Letter for Trexima(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Oct 2007
POZEN Plans to Submit Response to Approvable Letter For Trexima(TM) Within the Next Ten Days
Biopharmaceuticals
 HSMN NewsFeed - 2 Aug 2007
FDA Issues Second Approvable Letter for Trexima(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Jun 2007
Trexima(TM) (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 May 2007
Trexima(TM) (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across Multiple Migraine Attacks
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 May 2007
Trexima(TM) (Sumatriptan/Naproxen Sodium) Provided Relief of Both Traditional and Non-traditional Migraine Symptoms
Biopharmaceuticals Neurology
 HSMN NewsFeed - 10 Jan 2007
POZEN Names Gilda M. Thomas as Senior Vice President and General Counsel
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Dec 2006
Pozen Expects to Submit Revised Response to Trexima(TM) (Sumatriptan/Naproxen Sodium) Approvable Letter by Year End
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Nov 2006
POZEN Submits Full Response to FDA Approvable Letter For Trexima(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Sep 2006
New Analysis Shows Patients Who Treat Their Migraine Pain Early With Trexima(TM) (Sumatriptan Succinate/Naproxen Sodium) Have Higher Sustained Pain-Free Rates Than Those Who Treat Late
Biopharmaceuticals
 HSMN NewsFeed - 20 Sep 2006
New Data Show Consistent Efficacy and Tolerability of Trexima(TM) (Sumatriptan Succinate/Naproxen Sodium) Across Multiple Migraine Attacks
Biopharmaceuticals
 HSMN NewsFeed - 20 Sep 2006
New Data Show Peak Concentration of Sumatriptan Occurred Earlier With Trexima(TM) (Sumatriptan Succinate/Naproxen Sodium) Compared to Imitrex(R) (Sumatriptan Succinate)
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 7

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 7 additional stories matching:
RT Technology
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!